Compare DexCom, Inc. (DXCM) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Freshworks Inc — how do they compare? DexCom, Inc. trades at $90.68 (market cap $33.79B), while Freshworks Inc trades at $11.61 (market cap $3.31B). The key difference: DexCom, Inc. is far larger — about 10.2× Freshworks Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | FRSH | |
|---|---|---|
Market Cap | $33.79B | $3.31B |
Sector | Health | Technology |
52-Week High | $89.53 | $13.97 |
52-Week Low | $54.84 | $6.88 |
Enterprise Value | $33.24B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Freshworks (FRSH) trades at $11.66, down 2.67% on the day, as the stock consolidates near key technical levels. The company demonstrates strong fundamental improvement with 16% revenue growth in Q2 2026 and achieving GAAP profitability for the first time this year. Recent positive developments include FedRAMP certification progress and Gartner leadership recognition, while analyst sentiment remains evenly split between Buy and Hold ratings with a $16.50 consensus price target representing significant upside potential.
The outlook appears favorable given Freshworks' transition to profitability, expanding AI capabilities, and strong EX business growth. Key risks include competitive pressures in the SaaS sector and the need to maintain recent momentum. With attractive valuation metrics and positive cash flow trends, the stock presents a compelling opportunity for investors seeking exposure to the growing service operations software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
